scholarly journals Analysis of oral hypoglycemic agents in the normative documents regulating the treatment of diabetes mellitus 2 type

2016 ◽  
Vol 0 (3(47)) ◽  
pp. 75-80
Author(s):  
L. V. Yakovleva ◽  
A. L. Bilyk
2016 ◽  
Vol 4 (2) ◽  
pp. 113-123 ◽  
Author(s):  
Ved Prakash Singh ◽  

Diabetes mellitus is one of the world’s major diseases and is the third leading cause of death in the United States after heart disease and cancer. In the India, about 2–6% population suffer from diabetes or related complication. Anti-diabetic drugs treat diabetes mellitus by lowering glucose levels in the blood. Mostly anti-diabetic drugs are administered orally except the insulin, exenatide, and pramlintide. There are different types of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, and many other factors. Treatments include the agents which increase the amount of insulin secreted by the pancreas, or increase the sensitivity of target organs to insulin, and agents which decrease the rate at which glucose is absorbed from the gastrointestinal tract. People are mainly focused on insulin, insulin analogues, oral hypoglycemic agents and various other complementary and alternate medicines to control the blood glucose levels in diabetes. The present review summarizes in brief about the drugs used for treatment of diabetes mellitus.


Author(s):  
Suraj Rawate

Abstract: Globally and nationally the Diabetes mellitus with its complications become the most important contemporary and challenging health problem. It should be treated with diet and exercise, typically in conjunction with oral hypoglycemic drugs (OHD) and the complications are so critical and hazardous, and oral hypoglycemic agents and insulin which is used for the treatment of diabetes mellitus by the allopathic system of medicine have numerous side effects. In spite of available treatment number of patients is on rise. It is convincing that the herbal or mineral remedies stated in ayurveda used singly or in combination have potency in the treatment of madhumeha. However, our country is indeed rich in its vast variety of flora, throught variegated physical feature of the land, extending from mountains to the oceans. The practitioners of Indian system of medicine have been using the plant materials and are claiming success in treatment of madhumeha even today. Therefore, taking a lead it will be worthwhile to reappraise the commonly used plant remedies in the treatment of madhumeha, with an unbiased scientific spirit. In Ayurveda kaidarya is mentioned as parvata nimba. Nimba is the best drug used in Prameha. Edible variety of Nimba i.e curry leaves can be useful. Kaidarya is having katu, tikta, and kashaya rasa and sheeta veerya. It pacifies vitiated kapha and pitta. Kaidarya has been used traditionally since few years for treatment of prameha. Placebo control may not be ethical in the disease hence single arm study along with modern medicine is preffered. Keywords: Diabetes mellitus, kaidarya, Oral Hypoglycemic agents


2020 ◽  
Author(s):  
Cathline Layba ◽  
Lance Griffin

Diabetes mellitus is the seventh leading cause of death in the United States; diabetic patients have a 50% chance of undergoing a surgical procedure during their lifetime, and operations in this patient population have been associated with a reported mortality of 4% to 13%. Careful planning of operative management and perioperative care must be taken into account when scheduling surgery for diabetic patients, especially patients taking insulin or oral hypoglycemic agents. Debate continues and inconsistencies remain regarding the management of both diabetes and hyperglycemia in the surgical setting. The review covers the evaluation of the diabetic patient, preoperative management, intraoperative management, postoperative management, total parenteral nutrition and blood glucose, cardiovascular and renal assessment, infection, and special populations.  This review contains 2 figures, 5 tables, and 21 references Keywords: Glucose, Hyperglycemia, perioperative period, surgery, diabetes mellitus, surgical site infection, preoperative management, postoperative management, wound healing


2012 ◽  
Vol 58 (3) ◽  
pp. 56-60
Author(s):  
I R Iarek-Martynova

The onset of insulin therapy is an important stage in the treatment of type 2 diabetes mellitus. Its timely beginning ensures better control of glycemia and reduces the negative consequences of chronic glucose cytotoxicity and lipotoxicity. The achievement and maintenance of the stable compensation of the disease are the indispensable conditions for successful prophylaxis and adequate treatment of chronic complications of diabetes mellitus. The ADA guidelines recommend to initiate insulin therapy at the early stages of the disease provided it is dictated by the clinical situation or combine it with the use of oral hypoglycemic agents if the targeted HbA1c levels fail to be reached despite the intake of one or more tableted preparations.


Author(s):  
N. B. Zelinska ◽  
K. V. Grishchenko ◽  
E. V. Globa

Introduction. Recently, many studies have been devoted to the study of type 2 diabetes mellitus (DM2) worldwide. In most countries of the world, the increase in the prevalence of DM2 among children and adolescents is accompanied by an increase in childhood obesity. The presence of obesity or overweight in children can complicate the diagnosis of various types of DM. Detection and treatment of DM2 is extremely important for the society due to the wide range of severe diabetes complications.The aim of this work was to analyze the frequency of DM2 according to the Register of patients with DM, and to determine the state of glycemic control in children with DM2. Materials and methods. An analysis of glycemic control in children with DM2 who received various treatment regimens: with diet and lifestyle modifications, or with additional oral hypoglycemic agents (metformin monotherapy, or combination with insulin therapy). The glycemic control was assessed by measurement of glycated hemoglobin (HbA1c) level. Results. According to the data Register in Ukraine, the prevalence of DM among children has a tendency to rise — from 8.6 per 10 thousand children in 2005, to 13.14 — in 2019 year. The prevalence of DM2 in 2019 was 0.47 % of all cases of DM, and its prevalence contained 0.062 per 10 thousand children under 19 years of age with significant differences in the frequency of its diagnosis in different regions of Ukraine. We analyzed the state of glycemic control in children with DM2 aged from 9 up to 19 years old (Me 16.2 [15.5; 18.0]), with a  disease duration 0.5—12 years (Me 4.5 [1.0] ; 7.5]). The age of diagnosis of DM2 was 2-17 years old (Me 11.7 [8.5; 15.0]), and 91.3 % of patients had obesity. Diet and lifestyle modifications were used in 34.8 % of patients, metformin monotherapy in 52.2 %, and metformin and insulin combination therapy in 13 % of patients. HbA1c values ​​ranged from 5.0 to 11.4 % (Me 7.2 % [5,8; 8,0]). The proportion of children who had ideal or optimal glycemic control (HbA1c 7.0—7.5 %) was 52.2 %, suboptimal (HbA1c 7.6—9.0 %) — 39.1 %, high-risk glycemic control (HbA1c> 9.1 %) — 8.7 % of children. The most unsatisfactory HbA1c levels ​​were registered in children who received metformin in combination with insulin (Me 10.6 % [10,15; 11,4]). Chronic complications of DM2 have not been reported.Conclusions. We found a low prevalence of DM2 among the pediatric population in Ukraine, more likely due to the low quality of its detection among children diagnosed with DM, as well as among children among high risk groups. Most children with DM 2 were obese. The majority of patients with DM2 (52.2 %) received metformin monotherapy, more than a third did not receive oral hypoglycemic agents. In most children with DM2 (52,2 %), the state of glycemic control corresponded to the optimal (< 7.5 %), but higher levels of HbA1c were found children who received metformin in combination with insulin.


2021 ◽  
Vol 15 (12) ◽  
pp. 3427-3429
Author(s):  
Asim Hassan ◽  
Wedad Abullah Aldahasai ◽  
Shayma Abdulatif Alsalmi

Objectives: To get a clinical snapshot of the diabetic patients who planned to fast during the month of Ramadan and to determine the ability of the RRR application to effectively risk-stratify patients. Study Design: Observational study. Place and Duration of Study: Department of Diabetes & Endocrinology, Armed Forces Hospital Al-Hada, Taif, Kingdom of Saudi Arabia from 1st April 2018 to 31st May 2018. Methodology: Ninety six patients over 15 years of age with diabetes mellitus were risk stratified using standardized risk criteria were enrolled. Detailed analysis of the information was performed to paint a clinical landscape of the patients who intended to fast. Results: Seventy four percent of the patients were type 2 diabetics, 11% GDM, 31% were between 60-70 years and 17 % had diabetes for more than 20 years. 17% of participants had serious complications during the last three months before Ramadan including hypoglycemia, Diabetic Ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). 59% had chronic diabetic complications. 28 % of patients were on both insulin and oral hypoglycemic agents (OHA) together and 16 % on high risk medications. 25% of patients had an HbA1C of more than 10%. Pertaining to the previous Ramadan experience 19% disclosed having serious complications in the past. 6 % were categorized as low risk individuals, 76% as moderate, 6% high and 12 % as very high risk. Conclusions: Astonishingly all the patients advised to refrain from fasting insisted on fasting. Considering the latest IDF numbers the above calculated percentages would translate into very huge numbers who are in serious jeopardy. In order to prevent serious consequences it is highly recommends that evidence based and validated risk stratification strategies are implemented in routine clinical practices. Keywords: Diabetes mellitus, Fast, Hypoglycemia, High risk patients


Sign in / Sign up

Export Citation Format

Share Document